Compare Heron Therapeutics Inc (HRTX) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Energy Select Sector SPDR Fund — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Energy Select Sector SPDR Fund trades at $57.91. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | XLE | |
|---|---|---|
Market Cap | $91.46M | — |
Sector | Health | — |
52-Week High | $1.96 | $62.57 |
52-Week Low | $0.39 | $42.12 |
Enterprise Value | $189.36M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
XLE is trading at $57.96, up 0.49% with a bullish technical signal supported by strong moving average indicators. The energy ETF benefits from record refiner margins and geopolitical tensions driving oil prices higher. Recent news highlights XLE as a top-performing sector SPDR with 21% year-to-date gains, though RSI levels suggest potential overbought conditions near-term.
The energy sector outlook remains positive with Q2 earnings growth expectations and strong institutional support, though investors face risks from oil price volatility and geopolitical uncertainty. Technical resistance at $58-59 may limit immediate upside, while sector rotation and clean energy competition present longer-term considerations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
